Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Rare Disease Access topic
No spam. Unsubscribe anytime.
Committee advances 'Hope for Georgia Patients' bill to allow individualized experimental therapies for rare disease patients
Summary
The House Health Committee advanced the Hope for Georgia Patients Act, which supporters say would let clinicians in approved Georgia facilities use individualized experimental therapies for rare disease and certain cancer patients when conventional options are exhausted.
Senators and witnesses on the House Health Committee advanced legislation known in testimony as the Hope for Georgia Patients Act, a measure intended to create legal protections and a “safe harbor” that would let doctors and federally wide assurance‑approved facilities provide individualized treatments for patients with rare diseases and certain cancers.
Senator Brass, who presented the bill, said it would allow Georgia clinicians to use treatments “based on the individualized condition and DNA of the patient,” and would permit use of therapies that have not completed the traditional FDA approval process when those therapies are tailored to a single patient or very small numbers of patients. Brass said the bill includes consent provisions and other “guardrails” intended to protect patients.
Multiple witnesses urged passage. Kristen Connor, chief executive officer of Cure Childhood Cancer and a mother of a childhood cancer survivor, said the bill would give families access to potentially lifesaving, personalized therapies that are seldom pursued through standard FDA clinical trials because of the small number of affected patients. “This bill would allow [treatments] to be used right here in Georgia under strict medical supervision by the children who have no other options left,” Connor said.
A speaker identifying themselves as vice chair of the Myositis Association described family experience with a phase‑1 gene therapy that had positive safety results but lacked follow‑on funding for wider trials; that witness said the legislation “would have given [his family member] a chance.” Other supporting witnesses included the Georgia Faith and Freedom Coalition, which submitted a letter of support.
Committee members asked about limits and safety. Representative Newton noted guardrails in the bill that require physicians to consider currently FDA‑approved care first and to ensure informed consent; Brass confirmed the bill requires such consultations. Brass also said the measure explicitly excludes use of tissues from abortions and contains consent clauses.
The committee approved the bill by voice vote. The transcript records the committee advancing LC520746S SCS; the sponsor indicated he did not yet have a House sponsor secured at the time of the committee vote and asked for the chairman’s assistance.
Supporters framed the legislation as a way to allow Georgia residents to access individualized therapies at in‑state facilities rather than traveling to other states. The committee did not discuss a detailed budget impact, and the bill’s proponents said facilities using the therapies would be FWA‑approved and subject to ethical protections.
